GSK3B and neurodegenerative disease: Glycogen synthase kinase 3β (GSK3β) has emerged as one of the most attractive therapeutic targets for the treatment of neurodegenerative diseases, and GSK3β inhibitors have been successfully applied to the clinical practice for decades [1,2].